MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Nucleome Informatics Introduces a Novel Genetic Test for Inherited Retinal Diseases

NextEdge Admin

09 Sep 2024

2 min 32 sec

Nucleome Informatics, a leading genomics services provider, has launched the DrSeq IRD panel, a comprehensive genetic test for diagnosing inherited retinal diseases (IRDs). This novel test, one of the most advanced globally, aims to improve early detection and management, especially in individuals with a family history of blindness.

IRDs are a genetically diverse group of disorders that affect the retina, leading to vision impairment or blindness. In India, their prevalence varies between 1 in 350 to 1 in 2000, depending on factors like consanguinity. Diagnosing these conditions is challenging due to clinical and genetic heterogeneity, with over 300 genes linked to IRDs. The DrSeq IRD panel covers 850 genes and thousands of known and novel variants, offering exceptional diagnostic accuracy.

The test identifies genetic mutations responsible for specific IRD types, which is crucial for personalized treatment, including gene therapy. As gene therapies advance, genetic testing plays a vital role in helping patients access clinical trials and targeted therapies tailored to their genetic profiles.

In partnership with LV Prasad Eye Institute (LVPEI), the Department of Science and Technology (DST), and Korean collaborators, Nucleome Informatics developed the DrSeq IRD panel by sequencing 300 Indian IRD patients and 200 healthy family members. A similar study was conducted in Korea to validate its effectiveness.

Dushyant Singh Baghel, CEO of Nucleome Informatics, emphasized the test's role in advancing early detection, treatment options, and global gene therapy efforts for conditions like Leber congenital amaurosis, Stargardt’s disease, and retinitis pigmentosa. The company is actively seeking global distribution partners and gene therapy collaborators.